CAD pioneer partners with Sectra
R2 Technology and Swedish IT and medical technology company Sectra Imtec are customizing R2's computer-aided detection technology for use with the Sectra MicroDose digital mammography system. The focus of the agreement is R2's ImageChecker CAD
R2 Technology and Swedish IT and medical technology company Sectra Imtec are customizing R2's computer-aided detection technology for use with the Sectra MicroDose digital mammography system. The focus of the agreement is R2's ImageChecker CAD technology, which is designed to assist radiologists in the early detection of breast cancer and has already been incorporated into digital mammography systems from other vendors, including GE Medical Systems. The two companies plan to integrate CAD not only into the MicroDose mammography system but also into Sectra PACS for Breast Imaging. Under the agreement, Sectra will have exclusive worldwide distribution rights for three years to R2's CAD technology as applied to Sectra's MicroDose mammography system. The system is based on a highly efficient digital detector technology, which promises to reduce radiation dose by 80% or more without affecting image quality. Sectra recently invested more than $11 million in Stockholm-based Mamea Imaging, developer of the novel detector technology and ergonomic imaging stand that make up Sectra's low-dose digital mammography system (SCAN 1/8/04).
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
